Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Alistair Easton, Siim Pauklin, Susie Shapiro and their collaborators who have been awarded funding in the second round of the OxCODE Funding Scheme.

The Oxford Centre for Early Cancer Detection (OxCODE) Funding Scheme aims to advance innovative Oxford-based research that can be applied to detecting cancer earlier. OxCODE provides short-term awards that will enable the development of proof-of-concept projects, technologies, assays and platforms to a stage at which more long-term external funding can be sought. Priority was given to projects with a clear translational trajectory towards the ultimate longer-term goal of improving cancer patient care through earlier detection.

After peer review by the OxCODE Funding Scheme 2021 review group, the OxCODE Management Committee allocated funds to the following projects:

  • Dr Alistair Easton (Department of Oncology) “Multiplex immunofluorescence imaging: Developing a pipeline for early cancer phenotyping, diagnosis and research”.
  • Dr Siim Pauklin (Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences) “Early detection of pancreatic cancer by identifying exosome marker signatures in blood”.
  • Dr Susie Shapiro (MRC Weatherall Institute of Molecular Medicine and Oxford University Hospitals) “Unprovoked venous thromboembolism and early detection of increased blood cancer risk”

Congratulations to these teams and thank you to all applicants for their submissions.

Similar stories

Researchers develop new way to identify people with new-onset diabetes who are at risk of pancreatic cancer

The new method could help people with new-onset diabetes at high-risk of developing pancreatic cancer to be identified more accurately so that they can be monitored.